Shire Signs Non-Binding Agreement For New ADHD Phase III Compound

Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announces the signing of a non-binding initial agreement to globally develop and commercialize a new Attention Deficit Hyperactivity Disorder (ADHD) compound from New River Pharmaceuticals Inc... click link for more info.

Continue to Shire Signs Non-Binding Agreement For New ADHD Phase III Compound on Medical News Today.

Medical Buzz delivers the most recent headlines from the medical world. Diseases, cures, accidents, medicin. Click below for more headlines ...
Medical buzz